Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Lineage Tracing Reveals Clone-Specific Responses to Doxorubicin in Triple-Negative Breast Cancer [scRNA-seq]

ABSTRACT: Lineage Tracing Reveals Clone-Specific Responses to Doxorubicin in Triple-Negative Breast Cancer [scRNA-seq]

PROVIDER: PRJNA1234647 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR32658151_1.fastq.gz	Fastqsanger.gz
	SRR32658151_2.fastq.gz	Fastqsanger.gz
	SRR32658152_1.fastq.gz	Fastqsanger.gz
	SRR32658152_2.fastq.gz	Fastqsanger.gz
	SRR32658153_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 52

Similar Datasets

Lineage Tracing Reveals Clone-Specific Responses to Doxorubicin in Triple-Negative Breast Cancer

Project description:Triple-negative breast cancer, characterized by aggressive growth and high intratumor heterogeneity, presents a significant clinical challenge. Here, we use a lineage-tracing system, ClonMapper, which couples heritable clonal identifying tags with single-cell RNA-sequencing (scRNA-seq), to better elucidate the response to doxorubicin in a model of TNBC. We demonstrate that, while there is a dose-dependent reduction in overall clonal diversity, there is no pre-existing resistance signature among surviving clones. Separately, we found the existence of two transcriptomically distinct clonal subpopulations that remain through the course of treatment. Among clones persisting across multiple samples we identified divergent phenotypes, suggesting a response to treatment independent of clonal identity. Finally, a subset of clones harbor novel changes in expression following treatment. The clone and sample specific responses to treatment identified herein highlight the need for better personalized treatment strategies to overcome tumor heterogeneity.

2025-03-18 | GSE291679 | GEO

Lineage Tracing Reveals Clone-Specific Responses to Doxorubicin in Triple-Negative Breast Cancer

Project description:Lineage Tracing Reveals Clone-Specific Responses to Doxorubicin in Triple-Negative Breast Cancer

| PRJNA1234648 | ENA

Lineage Tracing Reveals Clone-Specific Responses to Doxorubicin in Triple-Negative Breast Cancer [scRNA-seq]

2025-03-18 | GSE291678 | GEO

Doxorubicin response in a triple negative breast cancer cell model: long-term resistance versus short-term stress

Project description:We have used a cell model for triple negative breast cancer, CAL51 cells, to study the transcriptional profiling of chemotherapy drug response. A doxorubicin resistant derivative has been generated, named CALDOX, which is able to proliferate in the continuos presence of 0.4 micro molar doxorubicin in the culture medium. In addition, both naive CAL51 and drug resistant CALDOX cells, the short-term response to doxorubicin treatment has been studied.

2023-02-27 | GSE202536 | GEO

Single cell lineage tracing reveals clonal dynamics of anti-EGFR therapy resistance in triple negative breast cancer

Project description:We investigate non-genomic mechanisms determining cellular response to EGFR inhibitors in triple negative breast cancer (TNBC). We integrate methods for cellular barcoding and single-cell transcriptomics to enable cell lineage tracing and explore the subclonal evolution of adaptation in an established preclinical model of TNBC in response to incremental concentrations of Afatinib, a second generation EGFR-TKI that irreversibly inhibits both EGFR and HER2. Retrospective lineage tracing data analysis uncovered a pre-existing subpopulation of rare Afatinib-tolerant cells displaying distinct biological features, such as elevated mRNA levels of the IGFBP2 gene. Furthermore, we investigated temporal coordination of transcriptional programs in drug resistant clones with high replication fitness by reordering cells along a pseudotime trajectory. Interestingly, it revealed the activation of biological processes, such as fatty acid metabolism, which have previously been linked to EGFR-TKIs resistance mechanisms.

2024-03-25 | GSE228154 | GEO

IL-17A increases doxorubicin efficacy in triple negative breast cancer

Project description:IL-17A increases doxorubicin efficacy in triple negative breast cancer

| PRJNA846314 | ENA

Proteomic analysis of triple negative breast cancer cell lines

Project description:We analysed aquired chemotherapeutic resistance of two different triple negative breast cancer cell lines BT-549 (Doxorubicin resistance) and MDA-MB-468 (5-Fluorouracil) by comparing the proteome of the parental cell line with the resistant cell line.

2018-02-23 | PXD008522 | Pride

IL-17A increases doxorubicin efficacy in triple negative breast cancer [bulk RNA-seq]

Project description:IL-17A increases doxorubicin efficacy in triple negative breast cancer [bulk RNA-seq]

| PRJNA846318 | ENA

Single cell lineage tracing reveals clonal dynamics of anti-EGFR therapy resistance in triple negative breast cancer

Project description:Single cell lineage tracing reveals clonal dynamics of anti-EGFR therapy resistance in triple negative breast cancer

| PRJNA948402 | ENA

Single cell lineage tracing reveals clonal dynamics of anti-EGFR therapy resistance in triple negative breast cancer.

Project description:Single cell lineage tracing reveals clonal dynamics of anti-EGFR therapy resistance in triple negative breast cancer.

| PRJNA949598 | ENA